Compare profiles
Pick two profiles and compare them side-by-side. Differences over ±10 pts are highlighted.
Profile A
Matching respondents
300/ 300 (100%)
Profile B
Matching respondents
300/ 300 (100%)
Information sources
- Peer-reviewed journals83%083%
- Discussions with peers83%083%
- Accredited Continuing Medical Education (CME) programs79%079%
- Clinical guideline websites69%069%
- Discussions with pharmaceutical company medical representatives (Medical Science Liaisons)58%058%
- Medical news websites52%052%
- In-person medical congresses51%051%
- AI tools/generative AI platforms (e.g., ChatGPT or other large language models)47%047%
- Speaker programs45%045%
- Live virtual congress sessions or webinars34%034%
First-choice formats
- Discussion with peers64%064%
- Full-length peer-reviewed journal articles61%061%
- Congress presentation or posters29%029%
- Short articles29%029%
- Live or on-demand expert discussions (e.g. Q&A, case discussions)29%029%
- Audio content or podcasts (e.g., on-demand expert interviews, congress recaps)28%028%
- Discussion with a Medical Science Liaison (MSL)25%025%
- 2–3-minute video summaries16%016%
- Infographics or one-page visual summaries12%012%
- Slide-based summaries (PPT/PDF)7%07%
MSL value moments
- After reviewing relevant data independently, to clarify questions ?or uncertainties30%030%
- To discuss upcoming pipeline developments22%022%
- To discuss complex treatment sequencing or decision-making20%020%
- As a follow-up after I requested medical info19%019%
- As a first introduction to new clinical or trial data17%017%
- To explore safety, tolerability, or real-world experience in more depth16%016%
- To explore how new data applies to specific patient types in my practice15%015%
- I do not typically find 1:1 discussions with pharmaceutical company representatives necessary13%013%
- To discuss clinical trial opportunities or research collaboration13%013%
Medical news
- Medscape35%035%
- OncLive29%029%
- ASCO Daily News26%026%
- Cancer Network23%023%
- Targeted Oncology23%023%
- ReachMD6%06%
- Healio Oncology5%05%
Social / professional
- Doximity22%022%
- Sermo14%014%
- X (Twitter)8%08%
- LinkedIn7%07%
Pre-congress preferences
- Expert perspectives on key topics expected to be discussed41%041%
- Refreshers on existing data or current treatment approaches38%038%
- Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%038%
- Study design overviews or key endpoints to watch32%032%
- Summaries of key trials to watch out for31%031%
Post-congress preferences
- Expert perspectives on key topics expected to be discussed41%041%
- Refreshers on existing data or current treatment approaches38%038%
- Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%038%
- Study design overviews or key endpoints to watch32%032%
- Summaries of key trials to watch out for31%031%